| R590. Insurance, Administration.
Effective 3-10-98 R590-132. Insurance Treatment of Human Immunodeficiency Virus (HIV) Infection. R590-132-1. Authority, Purpose and Scope. This rule is promulgated by the Insurance Commissioner pursuant to the authority provided under Subsections 31A-2-201(3) and (4), General Duties and Powers. The purpose of this rule is to identify and restrict certain underwriting, classification, or declination practices regarding HIV infection, that the commissioner finds are or would be unfairly discriminatory if engaged in. This rule also provides guidelines for the confidentiality of AIDS related testing, which, if not followed, would be unfairly discriminatory or hazardous to members of the insuring public. This rule applies to every licensee authorized to engage in the business of insurance in Utah under Title 31A of the Utah Code. R590-132-2. Definitions. 1. Presence of antibodies to HIV, verified by appropriate confirmatory tests. R590-132-3. Rule. TABLE Illustrative HIV Testing Informed Consent Form EXAMINER ........................................................ INSURER
......................................................... NOTICE AND CONSENT FOR TESTING
Unless precluded by law, tests may be performed to determine the presence of antibodies
or antigens to the Human Immunodeficiency Virus (HIV), also known as the AIDS virus. The
HIV antibody test performed is actually a series of tests done by a medically accepted
procedure. The HIV antigen test directly identifies AIDS viral particles. These tests are
extremely reliable. Other tests which may be performed include determinations of blood
cholesterol and related lipids (fats), screening for liver or kidney disorders, diabetes,
immune disorders, and other physical conditions. All test results will be treated confidentially. They will be reported by the
laboratory to the insurer. When necessary for business reasons in connection with
insurance you have or had applied for with the insurer, the insurer may disclose test
results to others such as its affiliates, reinsurers, employees, or contractors. If the
insurer is a member of the Medical Information Bureau (MIB, Inc.), and should the insurer
request an additional sample of bodily fluid for further testing, and you choose to
decline that request, your declination to be tested will be reported to the MIB, Inc.
Regardless of the number of tests requested, if the final test results for HIV
antibodies/antigens are other than normal, the insurer will report to the MIB, Inc. a
generic code which signifies only a non-specific abnormality. If your HIV test is normal,
no report will be made about it to the MIB, Inc. Other test results may be reported to the
MIB, Inc. in a more specific manner. The organizations described in this paragraph may
maintain the test results in a file or data bank. There will be no other disclosure of
test results or even that the tests have been done except as may be required or permitted
by law or as authorized by you. If your HIV test results are normal, no routine notification will be sent to you. If
the HIV test results are other than normal, the insurer will contact you. The insurer may
also contact you if there are other abnormal test results which, in the insurer's opinion,
are significant. The insurer may ask you for the name of a physician or other health care
provider to whom you may authorize disclosure and with whom you may wish to discuss the
results. The laboratory, physician or other health care provider will report positive test
results to the Health Department. If you have not designated a physician or other health
care provider to receive disclosure of positive test results, the insurer will report
positive test results to the health department. Positive HIV antibodies/antigen test results do not mean that you have AIDS, but that
you are at significantly increased risk of developing AIDS or AIDS-related conditions.
Federal authorities say that persons who are HIV antibody/antigen positive should be
considered infected with the AIDS virus and capable of infecting others. Positive HIV antibody or antigen test results or other significant abnormalities will
adversely affect your application for insurance. This means that your application may be
declined, that an increased premium may be charged, or that other policy changes may be
necessary. I have read and I understand this notice and consent for testing which may include HIV antibodies/antigen testing. I voluntarily consent to the withdrawal from me of blood
and/or other bodily fluid, the testing of that blood and/or other bodily fluid, and the
disclosure of the test results as described above. I understand that I have the right to request and receive a copy of this authorization.
A photocopy of this form will be as valid as the original. ................................................................................................................................................................ ............................................................................................................................................................ ............................................................................................... ............................................................................................... .............................................................................................. ............................................................................................. R590-132-4. Dissemination. Each insurer is instructed to distribute a copy of this rule or an equivalent summary to all personnel engaged in activities requiring knowledge of this rule, and to instruct them as to its scope and operation. R590-132-5. Penalties. Any licensee that violates this rule will be subject to the forfeiture provisions set forth in Section 31A-2-308 and 31A-23-216. R590-132-6. Confidentiality. Except as outlined in R590-132-3(D) above, all positive or indeterminate records of the applicant held by the licensee that refer to the HIV status shall be held as confidential records under restricted access and will not be re-released unless re-disclosure is specifically authorized by the applicant. Re-release and Re-disclosure are required when the test results are to be used for purposes other than those included in the initial release. R590-132-7. Severability. If any provision of this rule or its application to any person is for any reason held to be invalid, the remainder of the rule and the application of any provision to other persons or circumstances shall not be affected. KEY: insurance law 31A-2-201 |